Medifast (MED) 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 11, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'MED	'
Entity Common Stock, Shares Outstanding	'	12,739,149
Entity Registrant Name	'MEDIFAST INC	'
Entity Central Index Key	'0000910329	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$32,019,000	$36,382,000
Accounts receivable-net of allowance for sales returns and doubtful accounts of $547,000 and $647,000 at June 30, 2014 and December 31, 2013, respectively	1,693,000	1,246,000
Inventory	17,579,000	18,059,000
Investment securities	36,552,000	31,420,000
Prepaid expenses and other current assets	2,351,000	2,890,000
Deferred tax assets	2,062,000	1,957,000
Total current assets	92,256,000	91,954,000
Property, plant and equipment - net	37,080,000	40,336,000
Other assets	400,000	360,000
TOTAL ASSETS	129,736,000	132,650,000
Current liabilities:	'	'
Accounts payable and accrued expenses	25,209,000	26,780,000
Income taxes payable	575,000	99,000
Current maturities of capital leases	227,000	222,000
Total current liabilities	26,011,000	27,101,000
Other liabilities:	'	'
Capital leases, net of current portion	359,000	474,000
Deferred tax liabilities	5,859,000	6,659,000
Total liabilities	32,229,000	34,234,000
Stockholders' Equity:	'	'
Preferred stock, $.001 par value (1,500,000 authorized, no shares issued and outstanding)	0	0
Common stock; par value $.001 per share; 20,000,000 shares authorized; 13,176,018 and 13,143,309 issued at June 30, 2014 and December 31, 2013, respectively; 12,718,351 and 13,115,642 issued and outstanding at June 30, 2014 and December 31, 2013, respectively	13,000	13,000
Additional paid-in capital	1,446,000	0
Accumulated other comprehensive income	887,000	703,000
Retained earnings	109,387,000	97,700,000
Less: cost of 451,000 and 0 shares of common stock in treasury	-14,226,000	0
Total stockholders' equity	97,507,000	98,416,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$129,736,000	$132,650,000

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accounts receivable, allowance for sales returns and doubtful accounts	$547,000	$647,000
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	20,000,000	20,000,000
Common stock, issued	13,176,018	13,143,309
Common stock, outstanding	12,718,351	13,115,642
Common stock in treasury, shares	451,000	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue	$80,883,000	$97,072,000	$167,412,000	$193,115,000
Cost of sales	20,523,000	24,142,000	43,118,000	47,776,000
Gross Profit	60,360,000	72,930,000	124,294,000	145,339,000
Selling, general, and administrative	52,948,000	62,289,000	108,186,000	126,120,000
Income from operations	7,412,000	10,641,000	16,108,000	19,219,000
Other income	'	'	'	'
Interest and dividend income, net	170,000	98,000	296,000	150,000
Other income	1,103,000	139,000	1,287,000	219,000
Nonoperating Income (Expense)	1,273,000	237,000	1,583,000	369,000
Income before income taxes	8,685,000	10,878,000	17,691,000	19,588,000
Provision for income taxes	2,965,000	3,805,000	6,004,000	6,582,000
Net income	$5,720,000	$7,073,000	$11,687,000	$13,006,000
Basic earnings per share	$0.44	$0.51	$0.89	$0.94
Diluted earnings per share	$0.44	$0.51	$0.89	$0.93
Weighted average shares outstanding -	'	'	'	'
Basic	13,050,346	13,863,043	13,111,348	13,836,087
Diluted	13,149,414	13,963,057	13,200,207	13,995,171

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net income	$5,720,000	$7,073,000	$11,687,000	$13,006,000
Other comprehensive income, net of tax	'	'	'	'
Change in fair value of marketable securities, net of tax	214,000	-412,000	317,000	-308,000
Adjustment for net (gains)/losses realized and included in net income, net of tax	-42,000	-122,000	-133,000	-185,000
Total change in unrealized gains/losses on marketable securities, net of tax	172,000	-534,000	184,000	-493,000
Other comprehensive income	172,000	-534,000	184,000	-493,000
Comprehensive income	$5,892,000	$6,539,000	$11,871,000	$12,513,000

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid- In Capital	Retained Earnings	Accumulated other comprehensive income	Treasury Stock
Balance at Dec. 31, 2013	$98,416,000	$13,000	$0	$97,700,000	$703,000	$0
Balance (in shares) at Dec. 31, 2013	'	13,143,309	'	'	'	'
Shares issued to executives and directors	'	32,709	'	'	'	'
Share-based compensation to executives and directors	1,407,000	'	1,407,000	'	'	'
Share-based compensation tax benefit	39,000	'	39,000	'	'	'
Treasury stock purchases	-14,226,000	'	'	'	'	-14,226,000
Net income	11,687,000	'	'	11,687,000	'	'
Net change in unrealized gain on investments	184,000	'	'	'	184,000	'
Balance at Jun. 30, 2014	$97,507,000	$13,000	$1,446,000	$109,387,000	$887,000	($14,226,000)
Balance (in shares) at Jun. 30, 2014	'	13,176,018	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income	$11,687,000	$13,006,000
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:	'	'
Depreciation and amortization	5,077,000	5,221,000
Realized gain on investment securities, net	-233,000	-198,000
Share-based compensation	1,407,000	1,151,000
Deferred income taxes	-1,030,000	-552,000
(Gain)/loss on disposal of fixed assets	-32,000	61,000
Changes in assets and liabilities which provided (used) cash:	'	'
Accounts receivable	-447,000	183,000
Inventory	480,000	4,823,000
Prepaid expenses and other current assets	539,000	314,000
Other assets	-55,000	708,000
Accounts payable and accrued expenses	-1,571,000	2,461,000
Income taxes	476,000	539,000
Net cash provided by operating activities	16,298,000	27,717,000
Cash Flow from Investing Activities:	'	'
Sale of investment securities	6,426,000	5,909,000
Purchase of investment securities	-11,016,000	-20,187,000
Sale of property and equipment	1,215,000	0
Purchase of property and equipment	-3,004,000	-5,577,000
Net cash used in investing activities	-6,379,000	-19,855,000
Cash Flow from Financing Activities:	'	'
Repayment of long-term debt and capital leases	-110,000	-3,504,000
Decrease in note receivable	15,000	12,000
Excess tax benefits from share-based compensation	39,000	98,000
Purchase of treasury stock	-14,226,000	0
Net cash used in financing activities	-14,282,000	-3,394,000
NET CHANGE IN CASH AND CASH EQUIVALENTS	-4,363,000	4,468,000
Cash and cash equivalents - beginning of the period	36,382,000	39,937,000
Cash and cash equivalents - end of period	32,019,000	44,405,000
Supplemental disclosure of cash flow information:	'	'
Interest paid	93,000	38,000
Income taxes paid	$6,499,000	$6,418,000

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	1	Basis of Presentation
	The condensed unaudited interim consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included. The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.
	The results of operations for the three months and six months ended June 30, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014. The accompanying condensed unaudited interim consolidated financial statements should be read in conjunction with the 2013 audited financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2013 (“2013 Form 10-K”), which should be read in conjunction with these consolidated financial statements.

Presentation_of_Financial_Stat

Presentation of Financial Statements	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Presentation of Financial Statements	'
	2	Presentation of Financial Statements
	The Company’s condensed consolidated financial statements include the accounts of Medifast, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Recent Accounting Pronouncements	'
	3	Recent Accounting Pronouncements
	We have considered all new accounting pronouncements and have concluded that there are no new pronouncements that may have a material impact on our results of operations, financial condition, or cash flows, based on current information, except for Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), requires the Company to recognize revenue for the transfer of goods or services to customers for the amount the Company expects to be entitled in exchange for those goods or services. The Company will be required to identify the contract, identify the relevant performance obligations, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when the entity satisfies a performance obligation. Management is currently evaluating the effect that the provisions of ASU 2014-09 will have on the Company's financial statements.

Revenue_Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2014
Revenue Recognition [Abstract]	'
Revenue Recognition	'
	4	Revenue Recognition
	Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which primarily occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid for prior to shipping. Medifast Weight Control Centers’ program fees are recognized over the estimated service period.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	5	Inventories
	Inventories consist principally of packaged meal replacements held in the Company’s warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory.
	Inventories consisted of the following at June 30, 2014 and December 31, 2013:
			2014		2013
	Raw Materials		$	4,085,000	$	5,381,000
	Packaging			795,000		757,000
	Non-food Finished Goods			939,000		855,000
	Finished Goods			11,910,000		11,356,000
	Reserve for Obsolete Inventory			-150,000		-290,000
			$	17,579,000	$	18,059,000

Earnings_per_Share

Earnings per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	6	Earnings per Share
	Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of common shares outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of common shares outstanding adjusted for the effect of dilutive common stock equivalents.
	The following table sets forth the computation of basic and diluted EPS for the three and six months ended June 30:
			Three Months Ended June 30,				Six Months Ended June 30,
			2014		2013		2014		2013
	Numerator:
	Net income		$	5,720,000	$	7,073,000	$	11,687,000	$	13,006,000
	Denominator:
	Weighted average shares of common stock outstanding			13,050,346		13,863,043		13,111,348		13,836,087
	Effect of dilutive common stock equivalents			99,068		100,014		88,859		159,084
	Weighted average diluted common shares outstanding			13,149,414		13,963,057		13,200,207		13,995,171
	EPS:
	Basic		$	0.44	$	0.51	$	0.89	$	0.94
	Diluted		$	0.44	$	0.51	$	0.89	$	0.93
	The company had  70,542 anti-dilutive options for the three and six months ended June 30, 2014.

Estimates

Estimates	6 Months Ended
	Jun. 30, 2014
Estimates [Abstract]	'
Estimates	'
	7	Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Financial_Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2014
Investments, All Other Investments [Abstract]	'
Financial Instruments	'
		8	Financial Instruments
	Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:
	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
	Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
	Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.
	The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of June 30, 2014 and December 31, 2013:
			30-Jun-14
			Cost		Unrealized		Unrealized		Accrued		Estimated		Cash & Cash		Investment
					Gains		Losses		Interest		Fair Value		Equivalents		Securities
	Cash		$	30,971,000	$	-	$	-	$	-	$	30,971,000	$	30,971,000		-
	Level 1:
	Money Market Accounts			1,048,000		-		-		-		1,048,000		1,048,000		-
	Mutual Funds			9,917,000		212,000		-52,000		-		10,077,000		-		10,077,000
	Corporate Equity Securities			4,776,000		1,122,000		-52,000		-		5,846,000		-		5,846,000
	Government & Agency Securities			7,669,000		94,000		-13,000		29,000		7,779,000		-		7,779,000
				23,410,000		1,428,000		-117,000		29,000		24,750,000		1,048,000		23,702,000
	Level 2:
	Municipal Bonds			4,412,000		104,000		-6,000		37,000		4,547,000		-		4,547,000
	Corporate Bonds			8,167,000		87,000		-8,000		57,000		8,303,000		-		8,303,000
				12,579,000		191,000		-14,000		94,000		12,850,000		-		12,850,000
	Total		$	66,960,000	$	1,619,000	$	-131,000	$	123,000	$	68,571,000	$	32,019,000	$	36,552,000
			31-Dec-13
			Cost		Unrealized		Unrealized		Accrued		Estimated		Cash & Cash		Investment
					Gains		Losses		Interest		Fair Value		Equivalents		Securities
	Cash		$	30,958,000	$	-	$	-	$	-	$	30,958,000	$	30,958,000		-
	Level 1:
	Money Market Accounts			5,424,000		-		-		-		5,424,000		5,424,000		-
	Mutual Funds			7,887,000		127,000		-164,000		-		7,850,000		-		7,850,000
	Corporate Equity Securities			4,614,000		1,076,000		-9,000		-		5,681,000		-		5,681,000
	Government & Agency Securities			6,112,000		62,000		-43,000		26,000		6,157,000		-		6,157,000
				24,037,000		1,265,000		-216,000		26,000		25,112,000		5,424,000		19,688,000
	Level 2:
	Municipal Bonds			3,524,000		103,000		-		25,000		3,652,000		-		3,652,000
	Corporate Bonds			7,995,000		74,000		-47,000		58,000		8,080,000		-		8,080,000
				11,519,000		177,000		-47,000		83,000		11,732,000		-		11,732,000
	Total		$	66,514,000	$	1,442,000	$	-263,000	$	109,000	$	67,802,000	$	36,382,000	$	31,420,000

Sharedbased_Compensation

Shared-based Compensation	6 Months Ended
	Jun. 30, 2014
Share-Based Compensation [Abstract]	'
Shared-based Compensation	'
		9	Shared-based Compensation
	Stock Options:
	The Company has issued non-qualified and incentive stock options to employees and nonemployee directors. The fair value of these are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the expected volatility of the price of the Company’s common stock, dividend yield and the risk-free interest rate. Options outstanding as of June 30, 2014 vest over a period of three years with an expiration term of ten years. The exercise price of these options ranges from is $24.26 to 28.81. The expected volatility is based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. Due to the Company’s lack of option exercise history, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each award. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the expected term of the option. The Company historically has not issued dividends and therefore does not utilize a dividend yield in the calculation. The weighted average input assumptions used and resulting fair values were as follows:
		2014				2013
	Expected life (in years)			6				-
	Risk-free interest rate			1.61	%			-
	Expected volatility			63.15	%			-
	Dividend yield			-				-
	The following table summarizes the stock option activity:
			Shares			Weighted-Average			Weighted-Average		Aggregate
						Exercise Price			Remaining Contractual		Intrinsic
									Life (Yrs)		Value
	Outstanding at December 31, 2013			-		$	-
	Granted			70,542			26.11
	Exercised			-			-
	Outstanding at June 30, 2014			70,542		$	26.11			9.41		303,376
	Exerciseable at June 30, 2014			5,051		$	24.61			8.67		29,294
	The weighted-average grant date fair value of options granted was $15.19. The unrecognized compensation expense calculated under the fair value method for shares expected to vest as of June 30, 2014 was approximately $0.9 million and is expected to be recognized over a weighted average period of 2.5 years.
	Restricted Stock:
	The Company has issued restricted stock to employees and nonemployee directors generally with terms up to five years. The fair value is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes the restricted stock activity:
			Shares			Weighed-Average
						Grant Date Fair Value
	Unvested at December 31, 2013			393,532		$	24.23
	Granted			13,674			27.71
	Vested			-77,613			21.35
	Unvested at June 30, 2013			329,593		$	24.9
	The total options and restricted awards vested and charged against income during the three months ended June 30, 2014 and 2013 was $854,000 and $829,000, respectively and $1.6 million and $1.4 million for the six months ended June 30, 2014 and 2013. The Company accrued an additional $34,000 and $353,000 for performance awards for the three months ended June 30, 2014 and 2013, respectively and $372,000 and $833,000 for the six months ended June 30, 2014 and 2013, respectively. The cost of these awards will depend on the Company’s fiscal 2014 performance and will be finalized and approved at the first Board of Directors meeting in 2015. The current cost recognized is based on the performance that management expects the Company will achieve as of June 30, 2014. The total income tax benefit recognized in the consolidated statement of income for these restricted stock awards was approximately $301,000 and $282,000 for the three months ended June 30, 2014 and 2013, respectively and $573,000 and $468,000 for the six months ended June 30, 2014 and 2013, respectively. The total tax benefit recognized in additional paid-in capital upon vesting of restricted stock awards for the three and six months ended June 30, 2014 and 2013 was $39,000 and $98,000, respectively. There was approximately $6.3 million of total unrecognized compensation cost related to restricted stock awards as of June 30, 2014. The cost is expected to be recognized over a weighted-average period of approximately 3.2 years.

Business_Segments

Business Segments	6 Months Ended
	Jun. 30, 2014
Segment Reporting, Disclosure Of Entity's Reportable Segments [Abstract]	'
Business Segments	'
		10	Business Segments
	Operating segments are components of an enterprise about which separate financial information is available that is regularly reviewed by the chief operating decision maker about how to allocate resources and in assessing performance. The Company has two reportable operating segments: Medifast, and MWCC and Wholesale. The Medifast reporting segment consists of the following distribution channels: Medifast Direct and Take Shape For Life. The MWCC and Wholesale segment includes of what is referred to in MD&A as “Medifast Weight Control Centers” as well as Medifast Wholesale Physicians.
	Total assets and operating expense not identified with a specific segment are listed as “Other” and include items such as auditors’ fees, attorney’s fees, stock compensation expense and corporate governance expense related to compliance with NYSE, Sarbanes Oxley and SEC regulations. Evaluation of the performance of operating segments is based on their respective income from operations before taxes. The accounting policies of the segments are the same as those of the Company. The presentation and allocation of assets, liabilities and results of operations may not reflect the actual economic costs of the segments as stand-alone businesses. If a different basis of allocation were utilized, the relative contributions of the segments might differ, but management believes that the relative trends in segments would likely not be impacted.
	The following tables present segment information for the three and six months ended June 30, 2014 and 2013:
			Three Months Ended June 30, 2014
			Medifast		MWCC &		Other		Consolidated
					Wholesale
	Revenues		$	69,254,000	$	11,629,000	$	-	$	80,883,000
	Cost of Sales			16,794,000		3,729,000		-		20,523,000
	Selling, General and Administrative Expense			40,212,000		8,448,000		1,746,000		50,406,000
	Depreciation and Amortization			1,983,000		503,000		56,000		2,542,000
	Interest(net) and other			46,000		-1,039,000		-280,000		-1,273,000
	Income before income taxes		$	10,219,000	$	-12,000	$	-1,522,000	$	8,685,000
	Segment Assets		$	74,955,000	$	11,644,000	$	43,137,000	$	129,736,000
			Three Months Ended June 30, 2013
			Medifast		MWCC &		Other		Consolidated
					Wholesale
	Revenues		$	82,907,000	$	14,165,000	$	-	$	97,072,000
	Cost of Sales			20,447,000		3,695,000		-		24,142,000
	Selling, General and Administrative Expense			49,199,000		8,788,000		1,712,000		59,699,000
	Depreciation and Amortization			1,829,000		693,000		68,000		2,590,000
	Interest(net) and other			49,000		3,000		-289,000		-237,000
	Income before income taxes		$	11,383,000	$	986,000	$	-1,491,000	$	10,878,000
	Segment Assets		$	84,593,000	$	14,043,000	$	43,805,000	$	142,441,000
			Six Months Ended June 30, 2014
			Medifast		MWCC &		Other		Consolidated
					Wholesale
	Revenues		$	143,363,000	$	24,049,000	$	-	$	167,412,000
	Cost of Sales			35,953,000		7,165,000		-		43,118,000
	Selling, General and Administrative Expense			83,023,000		16,858,000		3,228,000		103,109,000
	Depreciation and Amortization			3,955,000		1,010,000		112,000		5,077,000
	Interest(net) and other			27,000		-1,030,000		-580,000		-1,583,000
	Income before income taxes		$	20,405,000	$	46,000	$	-2,760,000	$	17,691,000
	Segment Assets		$	74,955,000	$	11,644,000	$	43,137,000	$	129,736,000
			Six Months Ended June 30, 2013
			Medifast		MWCC &		Other		Consolidated
					Wholesale
	Revenues		$	165,301,000	$	27,814,000	$	-	$	193,115,000
	Cost of Sales			40,670,000		7,106,000		-		47,776,000
	Selling, General and Administrative Expense			100,058,000		17,624,000		3,217,000		120,899,000
	Depreciation and Amortization			3,644,000		1,451,000		126,000		5,221,000
	Interest(net) and other			78,000		3,000		-450,000		-369,000
	Income before income taxes		$	20,851,000	$	1,630,000	$	-2,893,000	$	19,588,000
	Segment Assets		$	84,593,000	$	14,043,000	$	43,805,000	$	142,441,000

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
		11	Contingencies
	The Company filed a civil complaint on February 17, 2010 in the U.S. District Court (SD, Cal) against Barry Minkow and the Fraud Discovery Institute, Inc. (collectively, “Minkow”), iBusiness Reporting, and its editor William Lobdell, Tracy Coenen and Sequence, Inc. (collectively, “Coenen”), “Zee Yourself”, and Robert L. Fitzpatrick (“FitzPatrick”) for defamation, market manipulation and unfair business practices, alleging a scheme of market manipulation of Medifast stock for Defendants’ for monetary gain, and damaging the business reputation of Medifast and its Take Shape For Life division. Bradley T. MacDonald, former Executive Chairman of Medifast and a stockholder, joined the lawsuit individually.  The lawsuit seeks $270 million in compensatory damages, punitive damages, and ancillary relief. In March 2011, the District Court granted in part and denied in part certain Anti-SLAPP Motions to Strike (i.e. motions to dismiss) previously filed by all Defendants. The Company appealed that portion of the District Court’s ruling which dismissed its defamation claims against Minkow and Coenen in the 9th Circuit Court of Appeals. Defendant FitzPatrick’s motion was denied as to the Company’s defamation claim, and FitzPatrick appealed that portion of the Court’s ruling.  On June 4, 2014, the Panel of the 9th Circuit Court of Appeals issued a decision, denying FitzPatrick’s appeal and remanding to the District Court for further consideration; reversing the District Court’s decision as to Minkow and remanding for further consideration; denying MacDonald’s appeal in its entirety; and denying Medifast’s appeal as to Coenen.  The District Court now has jurisdiction over the matter and has scheduled a conference to discuss its status and how to proceed.  While the case as to Coenan has been dismissed, the Company fully intends to pursue the matter against Minkow and Fitzpatrick.

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories consisted of the following at June 30, 2014 and December 31, 2013:
		2014		2013
	Raw Materials	$	4,085,000	$	5,381,000
	Packaging		795,000		757,000
	Non-food Finished Goods		939,000		855,000
	Finished Goods		11,910,000		11,356,000
	Reserve for Obsolete Inventory		-150,000		-290,000
		$	17,579,000	$	18,059,000

Earnings_per_Share_Tables

Earnings per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share, Basic and Diluted	'
	The following table sets forth the computation of basic and diluted EPS for the three and six months ended June 30:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Numerator:
	Net income	$	5,720,000	$	7,073,000	$	11,687,000	$	13,006,000
	Denominator:
	Weighted average shares of common stock outstanding		13,050,346		13,863,043		13,111,348		13,836,087
	Effect of dilutive common stock equivalents		99,068		100,014		88,859		159,084
	Weighted average diluted common shares outstanding		13,149,414		13,963,057		13,200,207		13,995,171
	EPS:
	Basic	$	0.44	$	0.51	$	0.89	$	0.94
	Diluted	$	0.44	$	0.51	$	0.89	$	0.93

Financial_Instruments_Tables

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments, All Other Investments [Abstract]	'
Cash and Available For Sale Securities Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses and Fair Value By Significant Investment Category	'
	The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of June 30, 2014 and December 31, 2013:
		30-Jun-14
		Cost		Unrealized		Unrealized		Accrued		Estimated		Cash & Cash		Investment
				Gains		Losses		Interest		Fair Value		Equivalents		Securities
	Cash	$	30,971,000	$	-	$	-	$	-	$	30,971,000	$	30,971,000		-
	Level 1:
	Money Market Accounts		1,048,000		-		-		-		1,048,000		1,048,000		-
	Mutual Funds		9,917,000		212,000		-52,000		-		10,077,000		-		10,077,000
	Corporate Equity Securities		4,776,000		1,122,000		-52,000		-		5,846,000		-		5,846,000
	Government & Agency Securities		7,669,000		94,000		-13,000		29,000		7,779,000		-		7,779,000
			23,410,000		1,428,000		-117,000		29,000		24,750,000		1,048,000		23,702,000
	Level 2:
	Municipal Bonds		4,412,000		104,000		-6,000		37,000		4,547,000		-		4,547,000
	Corporate Bonds		8,167,000		87,000		-8,000		57,000		8,303,000		-		8,303,000
			12,579,000		191,000		-14,000		94,000		12,850,000		-		12,850,000
	Total	$	66,960,000	$	1,619,000	$	-131,000	$	123,000	$	68,571,000	$	32,019,000	$	36,552,000
		31-Dec-13
		Cost		Unrealized		Unrealized		Accrued		Estimated		Cash & Cash		Investment
				Gains		Losses		Interest		Fair Value		Equivalents		Securities
	Cash	$	30,958,000	$	-	$	-	$	-	$	30,958,000	$	30,958,000		-
	Level 1:
	Money Market Accounts		5,424,000		-		-		-		5,424,000		5,424,000		-
	Mutual Funds		7,887,000		127,000		-164,000		-		7,850,000		-		7,850,000
	Corporate Equity Securities		4,614,000		1,076,000		-9,000		-		5,681,000		-		5,681,000
	Government & Agency Securities		6,112,000		62,000		-43,000		26,000		6,157,000		-		6,157,000
			24,037,000		1,265,000		-216,000		26,000		25,112,000		5,424,000		19,688,000
	Level 2:
	Municipal Bonds		3,524,000		103,000		-		25,000		3,652,000		-		3,652,000
	Corporate Bonds		7,995,000		74,000		-47,000		58,000		8,080,000		-		8,080,000
			11,519,000		177,000		-47,000		83,000		11,732,000		-		11,732,000
	Total	$	66,514,000	$	1,442,000	$	-263,000	$	109,000	$	67,802,000	$	36,382,000	$	31,420,000

Sharedbased_Compensation_Table

Shared-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Share-Based Compensation [Abstract]	'
Schedule of Assumptions Used	'
	The weighted average input assumptions used and resulting fair values were as follows:
		2014				2013
	Expected life (in years)			6				-
	Risk-free interest rate			1.61	%			-
	Expected volatility			63.15	%			-
	Dividend yield			-				-
Schedule of Share-based Compensation, Stock Options, Activity	'
	The following table summarizes the stock option activity:
			Shares			Weighted-Average			Weighted-Average		Aggregate
						Exercise Price			Remaining Contractual		Intrinsic
									Life (Yrs)		Value
	Outstanding at December 31, 2013			-		$	-
	Granted			70,542			26.11
	Exercised			-			-
	Outstanding at June 30, 2014			70,542		$	26.11			9.41		303,376
	Exerciseable at June 30, 2014			5,051		$	24.61			8.67		29,294
Restricted Stock Activity	'
	The following table summarizes the restricted stock activity:
			Shares			Weighed-Average
						Grant Date Fair Value
	Unvested at December 31, 2013			393,532		$	24.23
	Granted			13,674			27.71
	Vested			-77,613			21.35
	Unvested at June 30, 2013			329,593		$	24.9

Business_Segments_Tables

Business Segments (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting, Disclosure Of Entity's Reportable Segments [Abstract]	'
Segment Information	'
	The following tables present segment information for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended June 30, 2014
		Medifast		MWCC &		Other		Consolidated
				Wholesale
	Revenues	$	69,254,000	$	11,629,000	$	-	$	80,883,000
	Cost of Sales		16,794,000		3,729,000		-		20,523,000
	Selling, General and Administrative Expense		40,212,000		8,448,000		1,746,000		50,406,000
	Depreciation and Amortization		1,983,000		503,000		56,000		2,542,000
	Interest(net) and other		46,000		-1,039,000		-280,000		-1,273,000
	Income before income taxes	$	10,219,000	$	-12,000	$	-1,522,000	$	8,685,000
	Segment Assets	$	74,955,000	$	11,644,000	$	43,137,000	$	129,736,000
		Three Months Ended June 30, 2013
		Medifast		MWCC &		Other		Consolidated
				Wholesale
	Revenues	$	82,907,000	$	14,165,000	$	-	$	97,072,000
	Cost of Sales		20,447,000		3,695,000		-		24,142,000
	Selling, General and Administrative Expense		49,199,000		8,788,000		1,712,000		59,699,000
	Depreciation and Amortization		1,829,000		693,000		68,000		2,590,000
	Interest(net) and other		49,000		3,000		-289,000		-237,000
	Income before income taxes	$	11,383,000	$	986,000	$	-1,491,000	$	10,878,000
	Segment Assets	$	84,593,000	$	14,043,000	$	43,805,000	$	142,441,000
		Six Months Ended June 30, 2014
		Medifast		MWCC &		Other		Consolidated
				Wholesale
	Revenues	$	143,363,000	$	24,049,000	$	-	$	167,412,000
	Cost of Sales		35,953,000		7,165,000		-		43,118,000
	Selling, General and Administrative Expense		83,023,000		16,858,000		3,228,000		103,109,000
	Depreciation and Amortization		3,955,000		1,010,000		112,000		5,077,000
	Interest(net) and other		27,000		-1,030,000		-580,000		-1,583,000
	Income before income taxes	$	20,405,000	$	46,000	$	-2,760,000	$	17,691,000
	Segment Assets	$	74,955,000	$	11,644,000	$	43,137,000	$	129,736,000
		Six Months Ended June 30, 2013
		Medifast		MWCC &		Other		Consolidated
				Wholesale
	Revenues	$	165,301,000	$	27,814,000	$	-	$	193,115,000
	Cost of Sales		40,670,000		7,106,000		-		47,776,000
	Selling, General and Administrative Expense		100,058,000		17,624,000		3,217,000		120,899,000
	Depreciation and Amortization		3,644,000		1,451,000		126,000		5,221,000
	Interest(net) and other		78,000		3,000		-450,000		-369,000
	Income before income taxes	$	20,851,000	$	1,630,000	$	-2,893,000	$	19,588,000
	Segment Assets	$	84,593,000	$	14,043,000	$	43,805,000	$	142,441,000

Inventories_Detail

Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Schedule of Inventory [Line Items]	'	'
Raw Materials	$4,085,000	$5,381,000
Packaging	795,000	757,000
Non-food Finished Goods	939,000	855,000
Finished Goods	11,910,000	11,356,000
Reserve for Obsolete Inventory	-150,000	-290,000
Inventory	$17,579,000	$18,059,000

Earnings_per_Share_Detail

Earnings per Share (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator:	'	'	'	'
Net income	$5,720,000	$7,073,000	$11,687,000	$13,006,000
Denominator:	'	'	'	'
Weighted average shares of common stock outstanding	13,050,346	13,863,043	13,111,348	13,836,087
Effect of dilutive common stock equivalents	99,068	100,014	88,859	159,084
Weighted average diluted common shares outstanding	13,149,414	13,963,057	13,200,207	13,995,171
EPS:	'	'	'	'
Basic	$0.44	$0.51	$0.89	$0.94
Diluted	$0.44	$0.51	$0.89	$0.93

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive options	70,542	70,542

AvailableForSale_Securities_Ad

Available-For-Sale Securities Adjusted cost (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	$66,960,000	$66,514,000	'	'
Unrealized Gains	1,619,000	1,442,000	'	'
Unrealized Losses	-131,000	-263,000	'	'
Accrued Interest	123,000	109,000	'	'
Estimated Fair Value	68,571,000	67,802,000	'	'
Cash & Cash Equivalents	32,019,000	36,382,000	44,405,000	39,937,000
Investment Securities	36,552,000	31,420,000	'	'
Cash	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	30,971,000	30,958,000	'	'
Unrealized Gains	0	0	'	'
Unrealized Losses	0	0	'	'
Accrued Interest	0	0	'	'
Estimated Fair Value	30,971,000	30,958,000	'	'
Cash & Cash Equivalents	30,971,000	30,958,000	'	'
Investment Securities	0	0	'	'
Fair Value, Inputs, Level 1	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	23,410,000	24,037,000	'	'
Unrealized Gains	1,428,000	1,265,000	'	'
Unrealized Losses	-117,000	-216,000	'	'
Accrued Interest	29,000	26,000	'	'
Estimated Fair Value	24,750,000	25,112,000	'	'
Cash & Cash Equivalents	1,048,000	5,424,000	'	'
Investment Securities	23,702,000	19,688,000	'	'
Fair Value, Inputs, Level 1 | Money Market Accounts	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	1,048,000	5,424,000	'	'
Unrealized Gains	0	0	'	'
Unrealized Losses	0	0	'	'
Accrued Interest	0	0	'	'
Estimated Fair Value	1,048,000	5,424,000	'	'
Cash & Cash Equivalents	1,048,000	5,424,000	'	'
Investment Securities	0	0	'	'
Fair Value, Inputs, Level 1 | Mutual Funds	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	9,917,000	7,887,000	'	'
Unrealized Gains	212,000	127,000	'	'
Unrealized Losses	-52,000	-164,000	'	'
Accrued Interest	0	0	'	'
Estimated Fair Value	10,077,000	7,850,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	10,077,000	7,850,000	'	'
Fair Value, Inputs, Level 1 | Corporate Equity Securities	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	4,776,000	4,614,000	'	'
Unrealized Gains	1,122,000	1,076,000	'	'
Unrealized Losses	-52,000	-9,000	'	'
Accrued Interest	0	0	'	'
Estimated Fair Value	5,846,000	5,681,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	5,846,000	5,681,000	'	'
Fair Value, Inputs, Level 1 | Government Agency Securities	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	7,669,000	6,112,000	'	'
Unrealized Gains	94,000	62,000	'	'
Unrealized Losses	-13,000	-43,000	'	'
Accrued Interest	29,000	26,000	'	'
Estimated Fair Value	7,779,000	6,157,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	7,779,000	6,157,000	'	'
Fair Value, Inputs, Level 2	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	12,579,000	11,519,000	'	'
Unrealized Gains	191,000	177,000	'	'
Unrealized Losses	-14,000	-47,000	'	'
Accrued Interest	94,000	83,000	'	'
Estimated Fair Value	12,850,000	11,732,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	12,850,000	11,732,000	'	'
Fair Value, Inputs, Level 2 | Municipal Bonds	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	4,412,000	3,524,000	'	'
Unrealized Gains	104,000	103,000	'	'
Unrealized Losses	-6,000	0	'	'
Accrued Interest	37,000	25,000	'	'
Estimated Fair Value	4,547,000	3,652,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	4,547,000	3,652,000	'	'
Fair Value, Inputs, Level 2 | Corporate Bonds	'	'	'	'
Cash and Cash Equivalents and Marketable Securities [Line Items]	'	'	'	'
Cost	8,167,000	7,995,000	'	'
Unrealized Gains	87,000	74,000	'	'
Unrealized Losses	-8,000	-47,000	'	'
Accrued Interest	57,000	58,000	'	'
Estimated Fair Value	8,303,000	8,080,000	'	'
Cash & Cash Equivalents	0	0	'	'
Investment Securities	$8,303,000	$8,080,000	'	'

Schedule_of_Assumptions_Used_D

Schedule of Assumptions Used (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Expected life (in years)	'6 years	'0 years
Risk-free interest rate	1.61%	0.00%
Expected volatility	63.15%	0.00%
Dividend yield	0.00%	0.00%

Schedule_of_Share_Based_Compen

Schedule of Share Based Compensation Stock Options Activity (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Shares, Outstanding Beginning Balance	0
Shares, Granted	70,542
Shares, Exercised	0
Shares, Outstanding Ending Balance	70,542
Shares, Exerciseable	5,051
Weighted-Average Exercise Price, Outstanding Beginning Balance	$0
Weighted-Average Exercise Price, Granted	$26.11
Weighted-Average Exercise Price, Exercised	$0
Weighted-Average Exercise Price, Oustanding Ending Balance	$26.11
Weighted-Average Exercise Price, Exerciseable	$24.61
Weighted-Average Remaining Contractual Life (Yrs), Outstanding	'9 years 4 months 28 days
Weighted-Average Remaining Contractual Life (Yrs), Exerciseable	'8 years 8 months 1 day
Aggregate Intrinsic Value, Outstanding	$303,376
Aggregate Intrinsic Value, Exerciseable	$29,294

Summary_of_Restricted_Stock_Ac

Summary of Restricted Stock Activity (Detail) (Restricted Stock, USD $)	6 Months Ended
	Jun. 30, 2014
Restricted Stock	'
Shares	'
Unvested at December 31, 2013	393,532
Granted	13,674
Vested	-77,613
Unvested at June 30, 2014	329,593
Weighted-Average Grant Date Fair Value	'
Unvested at December 31, 2013	$24.23
Granted	$27.71
Vested	$21.35
Unvested at June 30, 2014	$24.90

Sharedbased_Compensation_Addit

Shared-based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized compensation cost related to restricted stock awards	$900,000	'	$900,000	'
Compensation cost recognition weighted average period	'	'	'2 years 6 months	'
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value	'	'	$15.19	'
Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit	'	'	$28.81	'
Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation, shares authorized under stock option plans, exercise price range, lower range limit	'	'	$24.26	'
Restricted Stock	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Restricted stock awards vested and charged	854,000	829,000	1,600,000	1,400,000
Total income tax benefit recognized related to restricted stock awards	301,000	282,000	573,000	468,000
Unrecognized compensation cost related to restricted stock awards	6,300,000	'	6,300,000	'
Compensation cost recognition weighted average period	'	'	'3 years 2 months 12 days	'
Share based compensation expense	34,000	353,000	372,000	833,000
Award vesting period	'	'	'5 years	'
Total Tax Benefit Recognized In Additional Paid-in Capital Upon Vesting Of Restricted Stock Awards	$39,000	$98,000	$39,000	$98,000

Business_Segments_Detail

Business Segments (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	$80,883,000	$97,072,000	$167,412,000	$193,115,000	'
Cost of Sales	20,523,000	24,142,000	43,118,000	47,776,000	'
Selling, General and Administrative Expense	50,406,000	59,699,000	103,109,000	120,899,000	'
Depreciation and Amortization	2,542,000	2,590,000	5,077,000	5,221,000	'
Interest(net) and other	-1,273,000	-237,000	-1,583,000	-369,000	'
Income before income taxes	8,685,000	10,878,000	17,691,000	19,588,000	'
Segment Assets	129,736,000	142,441,000	129,736,000	142,441,000	132,650,000
Medifast Inc	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	69,254,000	82,907,000	143,363,000	165,301,000	'
Cost of Sales	16,794,000	20,447,000	35,953,000	40,670,000	'
Selling, General and Administrative Expense	40,212,000	49,199,000	83,023,000	100,058,000	'
Depreciation and Amortization	1,983,000	1,829,000	3,955,000	3,644,000	'
Interest(net) and other	46,000	49,000	27,000	78,000	'
Income before income taxes	10,219,000	11,383,000	20,405,000	20,851,000	'
Segment Assets	74,955,000	84,593,000	74,955,000	84,593,000	'
MWCC & Wholesale	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	11,629,000	14,165,000	24,049,000	27,814,000	'
Cost of Sales	3,729,000	3,695,000	7,165,000	7,106,000	'
Selling, General and Administrative Expense	8,448,000	8,788,000	16,858,000	17,624,000	'
Depreciation and Amortization	503,000	693,000	1,010,000	1,451,000	'
Interest(net) and other	-1,039,000	3,000	-1,030,000	3,000	'
Income before income taxes	-12,000	986,000	46,000	1,630,000	'
Segment Assets	11,644,000	14,043,000	11,644,000	14,043,000	'
Other	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues	0	0	0	0	'
Cost of Sales	0	0	0	0	'
Selling, General and Administrative Expense	1,746,000	1,712,000	3,228,000	3,217,000	'
Depreciation and Amortization	56,000	68,000	112,000	126,000	'
Interest(net) and other	-280,000	-289,000	-580,000	-450,000	'
Income before income taxes	-1,522,000	-1,491,000	-2,760,000	-2,893,000	'
Segment Assets	$43,137,000	$43,805,000	$43,137,000	$43,805,000	'

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Loss Contingencies [Line Items]	'
Loss Contingency, Damages Sought, Value	$270